Hybridomas, which produce monoclonal antibodies, are made by fusing cells of the immune system with B lymphocytes and myeloma cells.
<h3>What are Hybridomas?</h3>
Large-scale production of monoclonal antibodies is made possible through hybridoma technology.
An antigen that triggers an immune response is first injected into a mammal to begin the process.
A specific sort of white blood cell called a B cell makes antibodies that bind to the antigen that has been injected.
These antibody-producing B-cells are then removed from the animal and combined with immortal B cell cancer cells, or myeloma, to create a hybrid cell line known as a hybridoma.
It possesses both longevity and procreative capacity of the myeloma and the antibody-producing capacity of the B-cell.
Hence, the creation of hybridomas, which result in the production of monoclonal antibodies, involves fusing immune system cells with B lymphocytes and myeloma cells.
